6:01 PM ET
Earnings Call
▶ Call
Acadia Pharmaceuticals Earnings Call: Key Takeaways
Acadia delivered strong Q3 results with 22% revenue growth, raised DAYBUE guidance, and optimized its Phase 3 ADP program despite a Phase 2 primary endpoint miss, supported by a $976 million cash position.
- Call
- Nov 4, 2026, 4:30 PM ET